Fortune Feature Published Monday July 20: 'The FDA's Peptide Vote Could Create Telehealth's Next Multibillion-Dollar Market' — The Story Frames the July 23-24 PCAC Vote as a Commercial Inflection Point for Hims & Hers, Ro, LifeMD, and Other GLP-1 Telehealth Platforms Looking for the Next High-Growth Category Beyond Compounded Semaglutide and Tirzepatide; Complements the Same-Day STAT News Investigation of LifeMD Alleging Volume-Over-Safety Practices in the GLP-1 Prescription Business
Fortune published Monday July 20, 2026 a feature framing the FDA Pharmacy Compounding Advisory Committee's July 23-24 peptide vote as a potential commercial inflection point for the telehealth industry. The article positions Hims & Hers (NYSE: HIMS), Ro, LifeMD (NASDAQ: LFMD), and other GLP-1 telehealth platforms as the natural commercial channels for legal peptide compounding if any of the seven peptides win 503A bulks-list eligibility. The commercial thesis: compounded GLP-1 volume has been the primary telehealth growth driver over 2024-2026, but the April 2025 FDA determination that semaglutide and tirzepatide shortages had resolved (and the April 30, 2026 proposed permanent 503B exclusion) closed the compounding channel for weight-loss demand; a favorable PCAC recommendation followed by FDA rulemaking would open a fresh compoundable-substance category (BPC-157, TB-500, KPV, MOTS-c, and others) that telehealth companies could sell into legally through licensed 503A pharmacies. The Fortune feature ran the same day as the STAT News investigation of LifeMD alleging former-employee patient-safety concerns; the two stories together frame the telehealth channel as simultaneously commercially opportunistic and clinically under scrutiny.